Spyre Therapeutics (SYRE) Current Assets (2015 - 2026)
Spyre Therapeutics (SYRE) posted Current Assets of $764.0 million for Q1 2026, down 1.78% on a QoQ basis from $777.8 million in Q4 2025, and up 34.08% year-over-year from $569.8 million in Q1 2025.
Spyre Therapeutics (SYRE) Current Assets (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Current Assets history runs 12 years deep, the most recent figure standing at $764.0 million for Q1 2026.
- Quarterly Current Assets rose 34.08% year-over-year to $764.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $764.0 million (up 34.08% YoY) and the FY2025 annual result came in at $777.8 million, up 27.82% from the prior year.
- Current Assets was $764.0 million for Q1 2026 at Spyre Therapeutics, down from $777.8 million in the prior quarter.
- Across five years, Current Assets topped out at $777.8 million in Q4 2025 and bottomed at $44.4 million in Q1 2023.
- A 5-year average of $367.8 million and a median of $421.1 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets sank 52.05% — and 2024, when it jumped 998.08%.
- Spyre Therapeutics' Current Assets stood at $62.3 million in 2022, then jumped by 448.57% to $341.5 million in 2023, then soared by 78.16% to $608.5 million in 2024, then rose by 27.82% to $777.8 million in 2025, then slipped by 1.78% to $764.0 million in 2026.
- Business Quant data shows SYRE's Current Assets at $764.0 million in Q1 2026, $777.8 million in Q4 2025, and $504.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 289.93 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 73.04 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 6.60 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 35.73 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 11.73 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 18.21 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 521.86 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 8.07 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.97 Bn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | 763.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 763.95 Mn |
| Dec 31, 2025 | 777.78 Mn |
| Sep 30, 2025 | 504.60 Mn |
| Jun 30, 2025 | 538.83 Mn |
| Mar 31, 2025 | 569.77 Mn |
| Dec 31, 2024 | 608.47 Mn |
| Sep 30, 2024 | 421.08 Mn |
| Jun 30, 2024 | 435.74 Mn |
| Mar 31, 2024 | 487.27 Mn |
| Dec 31, 2023 | 341.53 Mn |
| Sep 30, 2023 | 205.95 Mn |
| Jun 30, 2023 | 239.89 Mn |
| Mar 31, 2023 | 44.38 Mn |
| Dec 31, 2022 | 62.26 Mn |
| Sep 30, 2022 | 82.22 Mn |
| Jun 30, 2022 | 96.65 Mn |
| Mar 31, 2022 | 72.60 Mn |
| Dec 31, 2021 | 98.89 Mn |
| Sep 30, 2021 | 117.51 Mn |
| Jun 30, 2021 | 134.37 Mn |